Chimerigen

B7-H3(4Ig) [B7-H3b] (human) (rec.) (His)

CHF 390.00

In stock

CHI-HF-201B7H3B-C05050 µgCHF 390.00

More Information
Product Details
Product Type	Protein
Properties
Source/Host	HEK 293 cells
Sequence	Human B7-H3(4Ig) [B7-H3b] (aa 27-461) is fused at the C-terminus to a His-tag.
Crossreactivity	Human
Biological Activity	Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells.
MW	~65kDa (SDS-PAGE)
Purity	≥95% (SDS-PAGE)
Endotoxin Content	<0.01EU/μg protein (LAL test; Lonza).
Reconstitution	Reconstitute 50µg vial with 100 µl sterile water to a concentration of 0.5mg/ml. Add 1X PBS to the desired protein concentration.
Formulation	Lyophilized from 0.2μm-filtered solution in PBS.
Other Product Data	NCBI reference NP_001019907.1: B7-H3b (human)
Declaration	Manufactured by Chimerigen.
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS	Inquire
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

B7-H3(4Ig) or B7-H3b has two additional Ig-like domains (one V- type and one C- type) and shows a ubiquituous expression pattern. B7-H3(4Ig) is expressed on dendritic cells as well as activated T, B and NK cells. Human (4Ig) binding to an undefined receptor has shown to be inhibitory to NK cell illing and cytokine release. It also seems to be required for late stage osteoblast differentiation.

Call	+41 61 926 6040
Fax	+41 61 926 6049